Ruben Timmons, MD
Interventional Pain Medicine · Gulf Breeze, FLNPI 1376546572
Payments from drug & device makers
Across 24 payments — averaging $24.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$354
- Cook Medical LLC$66
- Nevro Corp.$54
- Bioventus LLC$25
- Relievant Medsystems, Inc.$20
- Redhill Biopharma Inc.$18
- plus $42 from 3 others
Across 12 payments — averaging $12,594 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cook Biotech Incorporated$151K
What the payments were for
- Food & beverage$579100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 14 | $354 |
| Cook Medical LLC | 1 | $66 |
| Nevro Corp. | 3 | $54 |
| Bioventus LLC | 1 | $25 |
| Relievant Medsystems, Inc. | 1 | $20 |
| Redhill Biopharma Inc. | 1 | $18 |
| Boston Scientific | 1 | $16 |
| Valinor Pharma, LLC | 1 | $14 |
| Lilly USA, LLC | 1 | $13 |
How this compares
$579 in reported general payments places this provider in the 15th percentile of 278 interventional pain medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NeurontinGabapentin | 11 | $30,415 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 873 | $19,821 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 257 | $8,252 |
| Gabapentin | 284 | $2,563 |
| Tramadol Hcl | 310 | $2,385 |
| Lidocaine | 24 | $2,299 |
| Fentanyl | 23 | $1,912 |
| Oxycodone Hcl | 103 | $1,613 |
| Tizanidine Hcl | 79 | $605 |
| Diclofenac Sodium | 36 | $598 |
| Methocarbamol | 52 | $428 |
| Baclofen | 25 | $404 |
| Duloxetine Hcl | 19 | $385 |
| Pregabalin | 36 | $356 |
| Cyclobenzaprine Hcl | 63 | $348 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Gulf Breeze
- Ajay AntonyGainesville$1.9M
- Louis RasoJupiter$1.6M
- Gilbert MbeoOrlando$1.4M
- George BesongOrange City$1.2M
- Gary KaoMiddleburg$1.1M
- Neil EllisTampa$1.1M
- Alexis RentaBoynton Beach$1.1M
- Michael EspositoVero Beach$1M
- Jose RiveraTampa$993K
- Nomen AzeemRiverview$691K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.